STOCK TITAN
  1. Home
  2. News
  3. ALKS

Alkermes plc - ALKS STOCK NEWS

Welcome to our dedicated news page for Alkermes plc (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alkermes plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alkermes plc's position in the market.

News
Alkermes to Report First Quarter Financial Results on May 1, 2024
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) will discuss its first quarter financial results in a conference call and webcast on May 1, 2024. Investors can access the webcast and slides on the company's website. The conference call details are provided for U.S. and international callers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Rhea-AI Summary
Alkermes plc announced positive topline results from a phase 1b study evaluating ALKS 2680 for narcolepsy type 2 and idiopathic hypersomnia. ALKS 2680 demonstrated significant improvements in mean sleep latency compared to placebo at all doses tested. The drug was well tolerated, supporting its advancement to a phase 2 study. The results show promise for treating sleep disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
clinical trial
-
News
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
Rhea-AI Summary
Alkermes plc (ALKS) announced the presentation of clinical data at the 2024 SIRS Congress on the long-term safety and efficacy of LYBALVI in treating schizophrenia and bipolar I disorder. Key findings include patient disposition, changes in weight and metabolic parameters, adverse events, and symptom stability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
News
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
Rhea-AI Summary
Alkermes plc appoints Nancy S. Lurker as a new independent director to its Board of Directors. Ms. Lurker, a seasoned healthcare executive, brings extensive pharmaceutical industry experience and commercial expertise to drive growth and innovation. The appointment reflects the company's commitment to board refreshment and aligning director qualifications with strategic goals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
management
-
News
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
Rhea-AI Summary
Alkermes plc reported total revenues of $1.66 billion in 2023 with an 18% increase in net sales of proprietary products. The company expects a 30% EBITDA margin in 2024. Key financial highlights include GAAP net income of $356 million and diluted GAAP earnings per share of $2.10 for 2023. Revenues from LYBALVI, ARISTADAi, and VIVITROL showed significant growth. The company also announced a new share repurchase program and provided financial expectations for 2024. Recent events include the completion of the oncology business separation, facility sale to Novo Nordisk, phase 3 study results of LYBALVI, and progress in the development of ALKS 2680 for narcolepsy treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.33%
Tags
earnings
-
News
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation to discuss the company's fourth quarter and year-end 2023 financial results, as well as financial expectations for 2024 and provide an update on the company. The event will take place at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 15, 2024. The webcast player and slides can be accessed on the Investors section of Alkermes' website, and the conference call can be accessed by dialing specific numbers. A replay of the webcast will also be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
conferences earnings
News
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) CEO Richard Pops to provide corporate update at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
-
News
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) announces positive topline results from phase 3 study on LYBALVI for long-term treatment of schizophrenia and bipolar I disorder
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
clinical trial
-
News
Corporate Governance at Alkermes
Rhea-AI Summary
Alkermes (ALKS) Corporate Responsibility Report Highlights Declassification of Board of Directors and Leadership Structure
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
none
News
Alkermes' Commitment to Integrity and Compliance
Rhea-AI Summary
Alkermes (ALKS) Corporate Responsibility Report Highlights Ethics and Compliance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
none
Stock ALKS logo
Alkermes plc

Nasdaq:ALKS

ALKS Rankings

#1320 Ranked by Market Cap
#1668 Ranked by Stock Gains
N/A Ranked by Dividends

ALKS Stock Data

4.02B
158.79M
1.25%
108.01%
8.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.